Herpes Zoster Clinical Trial
Official title:
Population Based Surveillance to Estimate the Burden of Herpes Zoster and Post-herpetic Neuralgia in Italy
NCT number | NCT01772160 |
Other study ID # | 116208 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | February 26, 2013 |
Est. completion date | October 5, 2016 |
Verified date | May 2020 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to collect data on the incidence, complications, economic burden and impact on the quality of life in adults aged ≥ 50 years with HZ disease in Italy.
Status | Completed |
Enrollment | 395 |
Est. completion date | October 5, 2016 |
Est. primary completion date | October 5, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility |
Inclusion Criteria: - A male or female = 50 years of age at the time of study enrolment presenting with acute HZ. - HZ diagnosis for this HZ episode: - Is his/her first outpatient diagnosis (i.e. initial consultation), OR - Took place at another site/centre (e.g. emergency room or Dermatologist/Specialist practice) provided the HZ diagnosis is not more than 7 days before the initial visit for the present study (i.e. secondary consultation). - Written informed consent obtained from the patient. - Ability to comply with study procedures. Exclusion Criteria: • Patient participating in another clinical study (participation in another observational, non-interventional trial is allowed). |
Country | Name | City | State |
---|---|---|---|
Italy | GSK Investigational Site | Alessandria | Piemonte |
Italy | GSK Investigational Site | Alessano (LE) | |
Italy | GSK Investigational Site | Angera (VA) | Lombardia |
Italy | GSK Investigational Site | Arcidosso (GR) | Toscana |
Italy | GSK Investigational Site | Arcisate (VA) | Lombardia |
Italy | GSK Investigational Site | Arezzo | Toscana |
Italy | GSK Investigational Site | Cavallino (LE) | Puglia |
Italy | GSK Investigational Site | Civitella Paganico (GR) | Toscana |
Italy | GSK Investigational Site | Comerio (VA) | Lombardia |
Italy | GSK Investigational Site | Copertino (LE) | Puglia |
Italy | GSK Investigational Site | Cutrofiano (LE) | Puglia |
Italy | GSK Investigational Site | Fagnano Olona (VA) | Lombardia |
Italy | GSK Investigational Site | Follonica (GR) | Toscana |
Italy | GSK Investigational Site | Frugarolo (AL) | Piemonte |
Italy | GSK Investigational Site | Galatina (LE) | Puglia |
Italy | GSK Investigational Site | Ghirla Valganna (VA) | Lombardia |
Italy | GSK Investigational Site | Grosseto | Toscana |
Italy | GSK Investigational Site | Induno Olona (VA) | Lombardia |
Italy | GSK Investigational Site | Lucignano (AR) | Toscana |
Italy | GSK Investigational Site | Montesano S. (LE) | Puglia |
Italy | GSK Investigational Site | Napoli | Campania |
Italy | GSK Investigational Site | Napoli | Campania |
Italy | GSK Investigational Site | Orbetello (GR) | Toscana |
Italy | GSK Investigational Site | Oviglio (AL) | Piemonte |
Italy | GSK Investigational Site | Parabita (LE) | Puglia |
Italy | GSK Investigational Site | Perugia | Umbria |
Italy | GSK Investigational Site | Perugia | Umbria |
Italy | GSK Investigational Site | Perugia | Umbria |
Italy | GSK Investigational Site | Ripa (PG) | Umbria |
Italy | GSK Investigational Site | Roma | Lazio |
Italy | GSK Investigational Site | Roma | Lazio |
Italy | GSK Investigational Site | Roma | Lazio |
Italy | GSK Investigational Site | Roma | Lazio |
Italy | GSK Investigational Site | Roma | Lazio |
Italy | GSK Investigational Site | Roma | Lazio |
Italy | GSK Investigational Site | Rome | |
Italy | GSK Investigational Site | Sale (AL) | Piemonte |
Italy | GSK Investigational Site | Sassofortino (GR) | Toscana |
Italy | GSK Investigational Site | Sesto Calende (VA) | Lombardia |
Italy | GSK Investigational Site | Solbiate Olona (VA) | Lombardia |
Italy | GSK Investigational Site | Specchia (LE) | Puglia |
Italy | GSK Investigational Site | Varese | Lombardia |
Italy | GSK Investigational Site | Villalvernia (AL) | Piemonte |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
Italy,
Salvetti A, Ferrari V, Garofalo R, Gazzaniga P, Guerroni A, Metrucci A, Sessa A, Severi ML, Nati G, Ruggeri M, Rossi A, Cappellari L, Gopala K, Tosatto R, Simone B. Incidence of herpes zoster and postherpetic neuralgia in Italian adults aged =50 years: A prospective study. Prev Med Rep. 2019 Apr 24;14:100882. doi: 10.1016/j.pmedr.2019.100882. eCollection 2019 Jun. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Incidence Rate of Herpes Zoster (HZ) Cases, by Age and Gender | A case of HZ was defined as new unilateral pain (broadly defined to include allodynia and pruritus) accompanied by unilateral rash and no alternative diagnosis. Age ranges were 50-54, 55-59, 60-64, 65-69, 70-74, 75-79 and greater than or equal to (=) 80 years. The incidence rate was expressed as the number of HZ cases per (/) 1000 person-years. | Day 0 to 2 years | |
Secondary | Percentage of Postherpetic Neuralgia (PHN) Cases Among HZ, Overall | PHN persistence refers to pain occurring or persisting from Day 90 to Day 270 after the rash onset. PHN was assessed via the Zoster Pain Inventory (ZBPI) questionnaire, which includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'. | At Day 90, 180 and 270 after onset of HZ | |
Secondary | General Medical History of Cases With HZ, Overall | General medical history focused on characteristics such as patient pre-existing condition and diseases (local trauma, diabetes mellitus, liver disease, alcoholism, renal failure/dialysis, emotional problems, stress or depression, blood malignancy, solid malignancy, hematopoetic cell/ bone marrow transplant, solid organ transplantation, HIV infection, hepatitis C under active therapy, autoimmune disease active and under therapy, other). | Between Day 0 and Day 270. | |
Secondary | Other General Medical History Characteristics for HZ Cases, Overall | Other general medical history characteristics referred to arterial problems, cerebral problems, gastric problems, gastric problems, prostate problems (arterial hypertension and allergic rhinitis, arterial hypertension and pacemaker, arteriopathy and past nun-Hodgkin lymphoma, atrial fibrillation, bronchopathy, cerebral thrombosis, cholecyst, chronic cerebral ischemia, chronic leukemia, chronic obstructive pulmonary disease, epilepsy, gastric lymphoma, gastropathy, hypertension, hypertension and hypothyroidism after surgery, hypertension dyslipidemia and hyperthyroidism, hypothyroidism hypertension, polycythaemia, polycythaemia from 10 years, prostate neoplasm, prostate oral anticoagulant therapy cardiopathy, prostatic cancer, right feet arthralgia, thrombocytopenia, vasculopathy chronic brain). | Between Day 0 and Day 270. | |
Secondary | Clinical Information of Cases With HZ, Overall | Clinical information of HZ cases referred to experience of any symptoms before rash, actual symptoms before rash (SBR), any complications at initial visit. | Between Day 0 and Day 270 | |
Secondary | Complications Related to HZ Cases, Overall | HZ related complications refer to cutaneous complications (Varicella Zoster Virus [VZV] dissemination, Bacterial superinfection), ocular (Loss of corneal sensation, Keratitis, Scleritis, Uveitis, Iridocyclitis), neurological (Meningo-encephalitis, Cranial nerve palsies, Peripheral nerve palsies, Ramsay-Hunt syndrome, Persistent HZ-related Pain), visceral [Neural extension of VZV infection (bronchitis, esophagitis,cystitis), VZV dissemination (pneumonia, arthritis, hepatitis] and other. | Between Day 0 and Day 270 | |
Secondary | Other Complications Related to HZ Cases, Overall | HZ related other complications refer to axillary lympagenopathy, burning sensation, hypoacusis, itching and rectum pain. | Between Day 0 and Day 270 | |
Secondary | Direct Medical Costs, Direct Non-medical Costs and Indirect Costs | Cost data related to HZ included medication, procedures and referral to hospital/specialist for direct medical costs, transport for direct non-medical costs and missed time from work, sick certificate for the indirect costs. | Up to Day 90 | |
Secondary | Worst Pain Assessment in HZ Subjects | The ZBPI is an assessment tool in the form of a questionnaire completed by the patient that is specifically designed to assess HZ-associated pain and discomfort. the ZBPI includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'. Note: The Day 90 window included assessments between Day 83 and Day 97 relative to day of rash onset. | At Day 90 | |
Secondary | Average Pain Assessment in HZ Subjects | The ZBPI is an assessment tool in the form of a questionnaire completed by the patient that is specifically designed to assess HZ-associated pain and discomfort. the ZBPI includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'. Note: The Day 90 window included assessments between Day 83 and Day 97 relative to day of rash onset. | At Day 90 | |
Secondary | Impact of HZ on Quality of Life as Assessed by the Zoster Pain Inventory | PHN persistence refers to pain occurring or persisting between 90-270 days after the rash onset. PHN was assessed via the Zoster Pain Inventory (ZBPI) questionnaire, which includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'. | At Day 0, 15, 30, 60, 90 | |
Secondary | Impact of HZ on Quality of Life as Assessed by the EuroQoL-Five Digits | EuroQoL-Five Digits (EQ-5D) is a standardised instrument for use as a measure of health outcome and is designed for self-completion by respondents. Its current format is 3-level and 5 dimensional (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The EQ-5D index was derived from the ratings recorded every 3 months for each of the five individual items (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The EQ-5D index/scale goes from 0 (worst health state) to 1 (perfect health state). | At Day 0, 15, 30, 60, 90 | |
Secondary | PHN Direct Medical Costs, Direct Non-medical Costs and Indirect Costs by Payer/Societal Perspective | Cost data related to HZ included medication, procedures and referral to hospital/specialist for direct medical costs, transport for direct non-medical costs and missed time from work, sick certificate for the indirect costs. | Between Day 90 and Day 270 | |
Secondary | Worst Pain Assessment in PHN Subjects | The ZBPI is an assessment tool in the form of a questionnaire completed by the patient that is specifically designed to assess HZ-associated pain and discomfort. the ZBPI includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'. Note: The Day 90 window included assessments between Day 83 and Day 97 relative to day of rash onset. | At Day 90 | |
Secondary | Average Pain Assessment in PHN Subjects | The ZBPI is an assessment tool in the form of a questionnaire completed by the patient that is specifically designed to assess HZ-associated pain and discomfort. The ZBPI includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'. Note: The Day 90 window included assessments between Day 83 and Day 97 relative to day of rash onset. | At Day 90 | |
Secondary | Impact of PHN on Quality of Life as Assessed by the Zoster Pain Inventory | PHN persistence refers to pain occurring or persisting between 90-270 days after the rash onset. PHN was assessed via the Zoster Pain Inventory (ZBPI) questionnaire, which includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'. | At Day 0, 15, 30, 60, 90 | |
Secondary | Impact of PHN on Quality of Life as Assessed by the EuroQoL-Five Digits | EuroQoL-Five Digits (EQ-5D) is a standardised instrument for use as a measure of health outcome and is designed for self-completion by respondents. Its current format is 3-level and 5 dimensional (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The EQ-5D index was derived from the ratings recorded every 3 months for each of the five individual items (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The EQ-5D index was 0 (worst health state) to 1 (best health state). | At Day 0, 15, 30, 60, 90 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03120364 -
Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over
|
Phase 3 | |
Completed |
NCT01165203 -
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
|
Phase 2 | |
Recruiting |
NCT06088745 -
A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine
|
Phase 3 | |
Completed |
NCT01385566 -
A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)
|
Phase 1 | |
Completed |
NCT01137669 -
ZOSTAVAX® in Renal Transplant Patients
|
Phase 1 | |
Completed |
NCT01911065 -
T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020
|
Phase 4 | |
Completed |
NCT00550745 -
ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)
|
Phase 4 | |
Completed |
NCT01132716 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions
|
N/A | |
Completed |
NCT01132729 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions
|
N/A | |
Completed |
NCT02852876 -
Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food
|
Phase 1 | |
Completed |
NCT00231816 -
A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)
|
Phase 3 | |
Completed |
NCT05082688 -
Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)
|
Phase 2 | |
Completed |
NCT04099706 -
Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT
|
N/A | |
Active, not recruiting |
NCT04091451 -
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) Who Had Prior Episode of Shingles
|
Phase 3 | |
Completed |
NCT02519855 -
Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)
|
Phase 3 | |
Completed |
NCT04523246 -
Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents
|
Early Phase 1 | |
Completed |
NCT05047770 -
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
|
Phase 3 | |
Completed |
NCT03314103 -
Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age
|
Phase 3 | |
Completed |
NCT01527370 -
Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)
|
Phase 3 | |
Completed |
NCT01954251 -
Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older
|
Phase 3 |